Stay updated with breaking news from Gerwin Winter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BRUKINSA is the only Bruton's Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)BRUKINSA is the only Bruton’s Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA® (ibrutinib) in relapsed/refractory CLL.BRUKINSA also showed...
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLLIf approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trialsWith significantly lower rates of atrial fibrillat...
Press release content from Business Wire. The AP news staff was not involved in its creation.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new